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Introduction {#nan12513-sec-0001}
============

Brain cholinergic neurotransmitter systems are instrumental in many behavioural and cognitive processes including attention, learning, memory, arousal and sleep [1](#nan12513-bib-0001){ref-type="ref"}, [2](#nan12513-bib-0002){ref-type="ref"}. As suggested in the 'Cholinergic hypothesis', a decreased level of acetylcholine in the cerebral cortex and hippocampus has been shown to contribute to the cognitive decline seen in ageing and Alzheimer\'s disease (AD) [3](#nan12513-bib-0003){ref-type="ref"}. The cholinergic innervation of the neocortex and allocortex originates from the cholinergic basal forebrain complex. In humans, this complex is composed of interdigitating cell groups with approximately 200 000 neurons per hemisphere [4](#nan12513-bib-0004){ref-type="ref"}, [5](#nan12513-bib-0005){ref-type="ref"}, [6](#nan12513-bib-0006){ref-type="ref"}.

Using acetylcholinesterase (AChE) histochemistry and choline acetyltransferase (ChAT) immunohistochemistry, Mesulam and colleagues introduced 'Ch' sectoral terminology to distinguish four groups of ChAT‐immunopositive neurons within the basal forebrain based on morphology and rostral--caudal organization [7](#nan12513-bib-0007){ref-type="ref"}, [8](#nan12513-bib-0008){ref-type="ref"}. Ch1--Ch4 correspond to the cholinergic neurons found in the medial septal nucleus (MSN), the nucleus of the vertical limb of the diagonal band of Broca (nvlDBB), the nucleus of the horizontal limb of the DBB (nhlDBB) and the nucleus basalis of Meynert (nbM), respectively. Retrograde tracer experiments using horseradish peroxidase in nonhuman primates showed that Ch1 and Ch2 provide cholinergic efferents to the hippocampal complex, Ch3 to the olfactory bulb and Ch4 to the neocortex and amygdala.

With over 90% of its magnocellular neurons being cholinergic, the nbM is the largest and most well‐studied cell group within the cholinergic basal forebrain. Degeneration of the nbM has been correlated with the presence of dementia in neurological conditions and we have previously hypothesized that subregions of the nbM are differentially affected in Parkinson\'s disease (PD) and AD [9](#nan12513-bib-0009){ref-type="ref"}. By contrast, pathology within the nvlDBB, which is the second largest cholinergic group in the basal forebrain and with up to 70% of neurons being ChAT‐positive, is much less well characterized in neurodegenerative conditions.

Given that hippocampal pathology is implicated in many dementing disorders and with the hippocampus receiving extensive innervation from the nvlDBB, it is important now to revisit this relatively neglected cholinergic cell group. Furthermore, there is a significant overlap between the nvlDBB and adjacent cholinergic loci, so there is as yet no clear consensus on its anatomical boundaries. Here, on the basis of a review of the history and anatomy of the rostral basal forebrain, we provide recommendations for the visualization and sampling of the human nvlDBB. In addition, we have reviewed clinicopathological studies involving the nvlDBB and postulate a role for cholinergic inputs from this nucleus in the cognitive decline seen in PD and AD.

Historical perspectives {#nan12513-sec-0002}
=======================

Coining the term diagonal band (of Broca) {#nan12513-sec-0003}
-----------------------------------------

In a series of monographs published in the 1870s and 1880s comparing the great limbic lobes (*Le grand lobe limbique*) in the brains of different mammalian species [10](#nan12513-bib-0010){ref-type="ref"}, [11](#nan12513-bib-0011){ref-type="ref"}, [12](#nan12513-bib-0012){ref-type="ref"}, French physician and anatomist Pierre Paul Broca defined a 'diagonal band' (*La bandelette diagonale*) within a quadrilateral space located directly superior to the optic chiasm (Figure [1](#nan12513-fig-0001){ref-type="fig"}). He described the band as seen from the inferior surface of the brain to run diagonally from the anterior and 'outermost' portion of the 'hippocampal lobe' to the root of the olfactory tract, joining the medial olfactory striae at the midline. On macrodissection, Broca related that the diagonal band passes in front of the optic chiasm and descends into the hemisphere. It then travels anterior to the anterior commissure and the medial septal fibres towards the genu of the corpus callosum. At a coronal level, this can be identified clearly as a white‐matter bundle medial to the nucleus accumbens of the basal ganglia (Figure [1](#nan12513-fig-0001){ref-type="fig"}). Further afield, the course of the diagonal band became difficult to follow, but Broca postulated that most of the fibres travel behind the corpus callosum and establish a direct connection between this lobe and the hippocampus. This projection is similar to the septal arcuate fibres described by Karl Friedrich Burdach in 1822 which is probably identical to the tract described by Broca [13](#nan12513-bib-0013){ref-type="ref"}. Sir Grafton Elliot Smith, an Australian‐British anatomist, acknowledged Broca\'s work and introduced the term DBB to the English literature [14](#nan12513-bib-0014){ref-type="ref"}.

![An illustration of the diagonal band (d--d′) in the human brain seen from the inferior surface, with the optic tract retracted, as described in Broca\'s monograph in 1888 [12](#nan12513-bib-0012){ref-type="ref"} (left). Coronal section at a level approximately 1.5 cm anterior to the mammillary bodies (red dashed line) revealed the extent of the diagonal band (black arrows) on both sides of the hemisphere, medial to the basal ganglia (right). Cd, caudate; IC, internal capsule; LV, lateral ventricle; nAcc, nucleus accumbens; PO, paraolfactory area; Pt, putamen.](NAN-44-647-g001){#nan12513-fig-0001}

Defining the 'nucleus' of the DBB {#nan12513-sec-0004}
---------------------------------

Previously mistaken as the medial paraolfactory nucleus, the nucleus of the DBB (nDBB) was first described in the brains of box turtles (*Cistudo Carolina*) as a cell mass extending from just rostral to the anterior commissure decussation down to the optic chiasm and caudal to the basolateral surface of the amygdaloid complex [15](#nan12513-bib-0015){ref-type="ref"}. Subsequently, the nDBB was described in alligators (*Alligator mississippiensis*) [16](#nan12513-bib-0016){ref-type="ref"}, opossums (*Didelphis virginiana*) [17](#nan12513-bib-0017){ref-type="ref"}, [18](#nan12513-bib-0018){ref-type="ref"}, rabbits [17](#nan12513-bib-0017){ref-type="ref"} and rats [19](#nan12513-bib-0019){ref-type="ref"}. The nDBB was also described in the brain of an 8‐month‐old human foetus in a comparative neuroanatomy study [17](#nan12513-bib-0017){ref-type="ref"}. Johnson reported that the nDBB started at the lower border of the septum pellucidum bounded laterally by the olfactory tubercle. He then described magnocellular and 'deeply stained' cells of the diagonal band extending 'laterally close beneath the internal capsule to the temporal limb of the anterior commissure'. He also noticed a bundle or tract which runs among the diagonal band cells ventral to the basal ganglia and parallel to the basal surface of the brain, descending into the temporal pole with the anterior commissure at its caudal end. Based on his description, it is likely that he was describing the nbM and that the bundle he described was not the diagonal band but was rather the ansa lenticularis and ansa peduncularis. This highlights the differential organization and localization of basal forebrain cell groups in different animal species. A large mass of nDBB cells seen in most other mammalian species is replaced by an extensive nbM in human and other nonhuman primates. It was not until the 1930s when comparative neuroanatomical study was performed on the brains of rhesus monkeys by Papez and Aronson that the primate nDBB was more properly defined [20](#nan12513-bib-0020){ref-type="ref"}. The authors noted the important distinction that the nDBB is a 'distinct band of deeply staining cells' embedded within and following the course of the DBB.

Subdivisions and the two 'limbs' of the DBB {#nan12513-sec-0005}
-------------------------------------------

Building on Papez\'s study, Herald Brockhaus was first to extensively characterize the nDBB (*die kerngruppe des diagonalen Bandes*) in humans in his comparative study of the basal forebrain cell groups (*Basalkernkomplex*) in primates [21](#nan12513-bib-0021){ref-type="ref"}. Based on the cell morphology, location and orientation, Brockhaus subdivided the nDBB rostrocaudally into the *nucleus diagonalis septalis*,*angularis* and *ventralis*. Subsequently, in a study of the septum in the human brain, Andy and Stephan divided the nDBB into 'tubercular' and 'septal' parts, with the septal part located against the medial septum, and the tubercular part located against the ventral aspect (olfactory tubercle) of the brain [22](#nan12513-bib-0022){ref-type="ref"}. In both subdivision schemes, the borders between subdivisions were arbitrarily defined and lack any functional significance.

Experimental lesioning of the fimbria‐fornix in rats, rabbits and the macaque monkey has demonstrated retrograde degeneration of the MSN and the nDBB, but limited to the vertical limb of the nucleus [23](#nan12513-bib-0023){ref-type="ref"}. Subsequently, division of the nDBB into vertical and horizontal limbs has become well accepted due to their distinct delineation and anatomical connections. Their distinct anatomical efferents were confirmed by retrograde tracer experiments, demonstrating that nvlDBB (along with MSN) projects to the hippocampal formation and nhlDBB projects to the olfactory bulb.

Anatomy of the nDBB {#nan12513-sec-0006}
===================

Extent of the diagonal band at different coronal levels {#nan12513-sec-0007}
-------------------------------------------------------

As described previously, the diagonal band emerges at the base of the brain and travels inward medially and rostrally to join the medial septal fibres by the genu of the corpus callosum. It is possible to map the extent of the diagonal band at several coronal levels rostrocaudally using established stereotaxic human brain atlases [24](#nan12513-bib-0024){ref-type="ref"}, [25](#nan12513-bib-0025){ref-type="ref"}, [26](#nan12513-bib-0026){ref-type="ref"} (Figure [2](#nan12513-fig-0002){ref-type="fig"}).

![Serial sections of human basal forebrain tissues at different coronal levels were stained with cresyl violet and luxol fast blue (CV/LFB) for the visualization of neurons and fibre tracts (**a**,**d**,**g**,**j**); H&E for identification of anatomical landmarks (**b**,**e**,**h**,**k**); and immunostained for ChAT (Millipore AB144P, 1:100 with antigen‐retrieval using pressure cooker pretreatment in pH6.0 citrate buffer) for the identification of the cholinergic population within the nvlDBB (**c**,**f**,**i**,**l**). The DBB was identified at four distinct levels, arranged rostrally (top) to caudally (bottom). (**a**--**c**) Precommissural level. At this level, the nucleus accumbens is prominent with the absence of anterior commissure fibre. The DBB can be seen at the medial and dorsal aspects, merging with the medial septum. Here, the Ch1 and Ch2 populations are often difficult to be distinguished. (**d**--**f**) Rostral predecussation level. The anterior commissure begins to emerge and the DBB is situated slightly more ventrally. ChAT‐positive neurons within the nvlDBB increase in density. (**g**--**i**) Caudal predecussation level. At this level, the DBB sits at the ventromedial aspect of the basal forebrain and the Ch2 population reaches the maximum. (**j**--**l**) Anterior commissure decussation level. Here, the anterior commissure begins to decussate and the DBB is situated ventrally, parallel to the ventral border of the basal forebrain. ChAT‐positive neurons of the nvlDBB intermingle with those in the nbM at this level. Asterisk (\*) denotes area of maximum density of ChAT‐positive neurons. BnST, bed nucleus of stria terminalis; Cd, caudate; ChAT, choline acetyltransferase; Ch1, cholinergic neurons in the medial septal nucleus; Ch2, cholinergic neurons in the vertical limb of the diagonal band of Broca; Ch4, cholinergic neurons in the nbM; nvlDBB, nucleus of the vertical limb of the DBB; EC, external capsule; GP, globus pallidus; IC, internal capsule; InCx, insular cortex; nAcc, nucleus accumbens; Pt, putamen; VS, ventral striatum; nbM, Nucleus basalis of Meynert.](NAN-44-647-g002){#nan12513-fig-0002}

At the rostral‐most level (here we term the 'pre‐commissural level' of the anterior basal ganglia due to the absence of anterior commissure fibre), the DBB can be identified dorsal and medial to the nucleus accumbens and interposed with the midline septum pellucidum (Figure [2](#nan12513-fig-0002){ref-type="fig"} **a**--**c**). Moving caudally, at the 'pre‐decussation level' (as the anterior commissure emerges laterally, but still anterior to the commissural decussation), the DBB descends ventrally but remains a compact white matter bundle situated within the ventromedial aspect of the basal forebrain (Figure [2](#nan12513-fig-0002){ref-type="fig"} **d**--**f**). More posteriorly, where the anterior limb of the anterior commissure becomes prominent, the DBB often splits into a much more diffuse structure, with its fibres often interspersed with streaks of grey matter (Figure [2](#nan12513-fig-0002){ref-type="fig"} **g**--**i**). At this level, the DBB is located lateral to a region known as the paraolfactory area [24](#nan12513-bib-0024){ref-type="ref"}, [25](#nan12513-bib-0025){ref-type="ref"} and the overall orientation of the white‐matter fibres become more diagonal. Here, the density of the ChAT‐positive neurons is greatest and correlates best with the *nucleus diagonalis angularis* described by Brockhaus [21](#nan12513-bib-0021){ref-type="ref"}. Finally, at the level of the anterior commissure decussation, the DBB terminates medial to the ventral striatum and the neurons are found to be orientated horizontally, parallel to the base of the forebrain (Figure [2](#nan12513-fig-0002){ref-type="fig"} **j**--**l**). The white‐matter fibres become very diffuse and it is probably at this coronal level that Broca described the diagonal band as seen from the base of the brain [12](#nan12513-bib-0012){ref-type="ref"}.

Sampling strategy for the nvlDBB {#nan12513-sec-0008}
--------------------------------

Exhaustive stereotaxic analysis of the entire diagonal band may be difficult due to limited availability of human brain tissue, particularly in clinical or tissue bank setting. Furthermore, the heterogeneity of cell density and anatomy do not lend themselves to sampling the entire extent. Instead, we propose that sampling a dense and reliably defined part of the nvlDBB would provide a more representative and accurate representation and enable consistent sampling of this important region. Depending on brain size, the area of maximal nvlDBB density is situated approximately 10--15 mm anterior to the coronal level of the mid‐mammillary body (Figure [3](#nan12513-fig-0003){ref-type="fig"}).

![Photograph showing two sliced brain slabs approximately 1.0 cm (right) and 1.5 cm (left) anterior to the coronal level of the mammillary bodies. Recommended sampling for the nvlDBB is outlined by a red box at the level at or just rostral to the anterior commissure decussation. nvlDBB, nucleus of the vertical limb of the diagonal band of Broca.](NAN-44-647-g003){#nan12513-fig-0003}

Due to the lack of clearly defined boundaries between overlapping cell groups within the basal forebrain cholinergic complex, the following guide can be used to distinguish the nvlDBB from surrounding basal forebrain nuclei (Table [1](#nan12513-tbl-0001){ref-type="table"}):

###### 

Guidelines for the identification of neurons within the nucleus of the vertical limb of the diagonal band of Broca

  Feature                                      Description
  -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Anteroposterior level at coronal plane**   Neurons can be identified at the 'pre‐decussation' level (Figure [2](#nan12513-fig-0002){ref-type="fig"} **d**,**g**) of the anterior basal ganglia
  **Dendritic orientation**                    Neurons are orientated at an oblique angle to the ventral border of the basal forebrain. Nucleus basalis of Meynert neurons are orientated parallel to the ventral border
  **Visibility of diagonal band**              Cells are embedded within the myelinated fibres of the diagonal band, identified on myelin counterstain or myelin‐stained serial sections
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First, isolated nvlDBB neurons are often found at the 'pre‐decussation' level (Figure [2](#nan12513-fig-0002){ref-type="fig"}). At the rostral‐most level (typically precommissural as shown in Figure [2](#nan12513-fig-0002){ref-type="fig"} **a**), the MSN forms a continuous, vertically orientated column of magnocellular neurons with the nvlDBB embedded within the septal grey matter. However, in contrast to the nvlDBB, only approximately 10% of MSN neurons are ChAT‐immunopositive. At this coronal level, previous authors have separated MSN from nvlDBB based on a rarefaction of ChAT‐immunostained neuron density [6](#nan12513-bib-0006){ref-type="ref"} and different neuronal morphology (with MSN neurons being generally smaller and ovoid in shape) [7](#nan12513-bib-0007){ref-type="ref"}. At the level of the anterior commissure decussation, the caudoventral part of the nvlDBB is often found to be interdigitated with the medial nbM magnocellular neurons, particularly the anteromedial sector of the Ch4 (Ch4am) [8](#nan12513-bib-0008){ref-type="ref"}.

Second, the direction of general dendritic orientation of the neurons is important for distinguishing nvlDBB from other neuronal groups. In a detailed morphometric study using thick (240 μm) basal forebrain sections with a Golgi impregnation technique, Arendt and colleagues [27](#nan12513-bib-0027){ref-type="ref"} described a gradual shift in dendritic orientation from a ventrodorsal orientation at the MSN and the rostral nvlDBB to a mediolateral orientation at the caudal nvlDBB and nbM. Neurons in the nvlDBB should be orientated at an oblique angle from the ventral border of the basal forebrain, which can be distinguished from those in the nbM which are orientated in a parallel fashion.

As suggested by various investigators, neurons in the nvlDBB are interspersed within the DBB [21](#nan12513-bib-0021){ref-type="ref"}, [25](#nan12513-bib-0025){ref-type="ref"}, [28](#nan12513-bib-0028){ref-type="ref"}, and counterstaining serial sections stained for myelin (luxol‐fast blue staining) can be helpful for identifying where the neurons reside with respect to the DBB fibre tracts.

A probabilistic approach to identify neurons within the nvlDBB {#nan12513-sec-0009}
--------------------------------------------------------------

Due to the overlapping arrangement of basal forebrain structures, intersubject variability may greatly affect delineation of nvlDBB from surrounding cholinergic cell groups. One approach to minimize uncertainty is to use a stereotaxic probabilistic map of brain structures, an approach popular among brain imaging scientists. This technique uses a small sample of serially and histologically stained, post‐mortem brain samples mapped on to a reference brain with magnetic resonance imaging (MRI) images, creating a probabilistic map, showing the likelihood for a certain structure found to be within a reference space in brain imaging [29](#nan12513-bib-0029){ref-type="ref"}. Probabilistic maps of various cortical and subcortical regions, including the basal forebrain, are presently available [29](#nan12513-bib-0029){ref-type="ref"}. Zaborszky and colleagues [30](#nan12513-bib-0030){ref-type="ref"} have published detailed stereotaxic probabilistic maps of the four basal forebrain cholinergic cell groups also including the often neglected posterior nbM (Ch4p) component in the mapping. However, in their study, no distinction was made between nvlDBB (Ch2) and MSN (Ch1). Furthermore, their initial delineation of the four cholinergic cell groups was largely based on Mesulam and colleagues' classification on rhesus monkeys [7](#nan12513-bib-0007){ref-type="ref"}, which may not reliably map well on to human brains. For future brain imaging studies focusing on the nvlDBB, a more detailed probabilistic map separating the nvlDBB and the MSN may be required.

Distinction between the anterior (rostral) and posterior (caudal) basal forebrain compartments {#nan12513-sec-0010}
----------------------------------------------------------------------------------------------

Although different basal forebrain compartments appear to be continuous, there have been suggestions that they are developed from a dual embryological origin. Based on observations in rats and cats, the caudal basal forebrain (including the nbM) arises earlier than the rostral components (MSN and nvlDBB) which later merge and form a continuum (reviewed in [2](#nan12513-bib-0002){ref-type="ref"}). Although it is unknown whether the same is true for humans, one could speculate that component‐specific vulnerability may exist in different neurological disorders. In one recent MRI study on patients with amnestic mild cognitive impairment and controls, Cantero and colleagues reported the volume changes in the rostral basal forebrain including the MSN and nvlDBB significantly correlated with changes in hippocampal volume in both groups, whereas that of the caudal basal forebrain only significantly correlated with variations of amygdala and temporal cortical volumes. Hence, in future studies, it is important to carefully delineate these basal forebrain nuclei and perform more in‐depth analysis.

What about the nucleus of the horizontal limb of the diagonal band? {#nan12513-sec-0011}
-------------------------------------------------------------------

Cells in the nhlDBB can be found both amongst the fibres of the horizontal portion of the DBB and beneath the substantia innominata, parallel to the ventral surface of the basal forebrain. They are described as generally smaller than nbM neurons (10--15 μm in diameter) and are fusiform and multipolar in shape [7](#nan12513-bib-0007){ref-type="ref"}, [31](#nan12513-bib-0031){ref-type="ref"}. However, in primates, only approximately 1% of the nhlDBB neurons are cholinergic, overlapping heavily with neurons in the nbM [7](#nan12513-bib-0007){ref-type="ref"} and understandably for studies of cholinergic innervation, this nucleus is often neglected.

Revisiting the cholinergic nvlDBB in different neurological diseases {#nan12513-sec-0012}
====================================================================

After establishing the anatomy of the nvlDBB, we carried out an extensive literature review to establish the pattern of cell loss within the nvlDBB in several neurological disorders. Due to the difficulty in delineating boundaries, some studies grouped the MSN and nvlDBB as they share a common efferent pathway towards the hippocampal complex [4](#nan12513-bib-0004){ref-type="ref"}, [32](#nan12513-bib-0032){ref-type="ref"}, [33](#nan12513-bib-0033){ref-type="ref"}, [34](#nan12513-bib-0034){ref-type="ref"}, [35](#nan12513-bib-0035){ref-type="ref"}, [36](#nan12513-bib-0036){ref-type="ref"}. Furthermore, most investigators have used the terminology Ch2 when quantifying neuronal loss within nvlDBB, though this term should strictly be used on ChAT‐immunostained tissue to define the local cholinergic population. Thus, in this review, we avoid using Ch terminology unless the particular study carried out quantitative assessment with a specific cholinergic marker.

The nvlDBB in AD {#nan12513-sec-0013}
----------------

Quantitative studies on the nvlDBB in AD have reported conflicting results ranging from no cell loss to a maximum of 84% loss (Table [2](#nan12513-tbl-0002){ref-type="table"}). Loss of nvlDBB neurons was mainly reported in earlier studies using cresyl violet (Nissl stain) for the visualization of neurons, and the degree of cell loss did not appear to differ between early and late‐onset AD [37](#nan12513-bib-0037){ref-type="ref"}. Neuronal loss in the nvlDBB was correlated to senile plaque density in the hippocampus of AD cases by one group [4](#nan12513-bib-0004){ref-type="ref"}, but this correlation was not observed in another study [37](#nan12513-bib-0037){ref-type="ref"}. It was later suggested that neurons within the basal forebrain cholinergic group undergo atrophy instead of cell loss in AD [34](#nan12513-bib-0034){ref-type="ref"}. Indeed, when size criteria were eliminated for the quantification of neurons within the nvlDBB, no significant cell loss was observed in AD cases relative to age‐matched controls. This is supported by the higher reported nvlDBB cell loss in studies only quantifying neurons larger than 30 μm in diameter (70--80% loss) [37](#nan12513-bib-0037){ref-type="ref"}, [38](#nan12513-bib-0038){ref-type="ref"} compared with those quantifying neurons larger than 20 μm in diameter (41--67.5% loss) [4](#nan12513-bib-0004){ref-type="ref"}, [32](#nan12513-bib-0032){ref-type="ref"}, [39](#nan12513-bib-0039){ref-type="ref"}, [40](#nan12513-bib-0040){ref-type="ref"}. Using appropriate immunohistochemistry, a size criterion to distinguish neurons from other cell types is not needed as both large and atrophied neurons will be stained, although the latter will only be positive if metabolically active and preserving a cholinergic phenotype. One study using immunohistochemistry to label nerve growth factor (NGF) receptors (NGFR), which coexpress in over 95% of the basal forebrain cholinergic neurons, failed to observe any significant neuronal loss in the nvlDBB in the seven AD cases studied [33](#nan12513-bib-0033){ref-type="ref"}. This is supported by a previous finding that NGF gene expression is decreased in the nbM but not the MSN and nvlDBB of AD cases [41](#nan12513-bib-0041){ref-type="ref"}. However, studies using ChAT immunohistochemistry on nvlDBB neurons reported contrasting results. An early study on four AD cases (mean age at death = 89.5) found 56% ChAT‐positive neuronal loss in the nvlDBB and 53% loss in the MSN with no significant change in mean neuronal cross‐sectional area [6](#nan12513-bib-0006){ref-type="ref"}, whereas a more contemporary study found neuronal shrinkage but no significant loss of Ch1/2 neurons in four AD cases (mean age at death = 83.5) [35](#nan12513-bib-0035){ref-type="ref"}. One explanation for these differences could be a differing sensitivity of anti‐ChAT antibodies and immunohistochemical amplification techniques. In Lehericy *et al*.\'s study, primary antibodies were incubated for 3 days prior to signal amplification with peroxidase antiperoxidase technique, possibly suggesting a lower sensitivity of the primary antibody used. Therefore, it is likely that neurons with a diminished expression of ChAT, particularly in AD [34](#nan12513-bib-0034){ref-type="ref"}, may not be stained and quantified. Nevertheless, there is a general consensus that this rostral cholinergic basal forebrain is relatively spared in AD.

###### 

Studies quantifying changes of the nvlDBB and MSN neurons

  Year                                                   Authors                                                        Stains for identification of neurons   Neuronal count criteria                                                      Disease                          *n*                                                                                                                           Mean age at death                      %nvlDBB loss from control                                                                                                                              %MSN loss from control   %nvlDBB + MSN loss from control
  ------------------------------------------------------ -------------------------------------------------------------- -------------------------------------- ---------------------------------------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ -----------------------------------------------------------------------------------------------------------------------------
  AD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1983                                                   Arendt *et al*. [39](#nan12513-bib-0039){ref-type="ref"}       Nissl                                  \>20 μm diameter, abundant Nissl substance                                   AD                               14                                                                                                                            60.8                                   67.50%                                                                                                                                                 63.71%                   --
  1985                                                   Arendt *et al*. [4](#nan12513-bib-0004){ref-type="ref"}        Nissl                                  \>20 μm diameter, abundant Nissl substance                                   AD                               5                                                                                                                             60.8                                   --                                                                                                                                                     --                       62.50%
  1986                                                   Etienne *et al*. [37](#nan12513-bib-0037){ref-type="ref"}      Nissl                                  \>30 μm diameter, visible nucleus, abundant Nissl substance                  AD                               9                                                                                                                             78.9                                   70% (mean); 83.56% (max)                                                                                                                               --                       --
  1987                                                   Gertz *et al*. [32](#nan12513-bib-0032){ref-type="ref"}        Nissl                                  \>20 μm diameter, nucleated nerve cells                                      AD                               7                                                                                                                             91.1                                   --                                                                                                                                                     --                       54.20%
  1988                                                   Wilcock *et al*. [40](#nan12513-bib-0040){ref-type="ref"}      Nissl                                  \>20 μm diameter, visible nucleolus, abundant Nissl substance                AD                               10                                                                                                                            79.3                                   41.09% (mean); 41.42% (max)                                                                                                                            --                       --
   1989                                                  Mufson *et al*. [33](#nan12513-bib-0033){ref-type="ref"}       NGFR                                   Immunoreactive cell soma                                                     AD                               7                                                                                                                             77                                     --                                                                                                                                                     --                       16.7% (n.s.)
  1990                                                   Vogels *et al*. [34](#nan12513-bib-0034){ref-type="ref"}       Nissl                                  Nissl‐stained, visible nucleolus                                             AD                               10                                                                                                                            84.5                                   --                                                                                                                                                     --                       No loss
   1993                                                  Lehericy *et al*. [6](#nan12513-bib-0006){ref-type="ref"}      ChAT                                   ChAT‐positive cell body (displaying either strong or light immunostaining)   AD                               4                                                                                                                             89.5                                   56%                                                                                                                                                    53%                      55%
  1995                                                   Arendt *et al*. [43](#nan12513-bib-0043){ref-type="ref"}       Nissl                                  \>20 μm diameter, visible nucleus, abundant Nissl substance                  AD                               15                                                                                                                            65                                     --                                                                                                                                                     --                       Approximately 78%[a](#nan12513-note-0004){ref-type="fn"} (*vs*. adult control); approximately 64.5% (*vs*. elderly control)
  1995                                                   Poirier *et al*. [38](#nan12513-bib-0038){ref-type="ref"}      Nissl & AChE                           AChE‐positive, \>30 μm, abundant Nissl substance on adjacent section         AD                               8 (from 24)                                                                                                                   Unknown for the eight selected cases   Approximately 60%[a](#nan12513-note-0004){ref-type="fn"} (ApoE4 negative); approximately 80%[a](#nan12513-note-0004){ref-type="fn"} (ApoE4 positive)   --                       --
   2006                                                  Fujishiro *et al*. [35](#nan12513-bib-0035){ref-type="ref"}    ChAT                                   ChAT‐immunopositive cells                                                    AD                               4                                                                                                                             83.5                                   --                                                                                                                                                     --                       n.s.
  Lewy body disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1983                                                   Whitehouse *et al*. [42](#nan12513-bib-0042){ref-type="ref"}   Nissl                                  \>30 μm diameter, abundant Nissl substance                                   PD                               3                                                                                                                             60                                     n.s.                                                                                                                                                   --                       --
  PDD                                                    2                                                              71.5                                   44.80%                                                                       --                               --                                                                                                                                                                                                                                                                                                                                                   
  1983                                                   Arendt *et al*. [39](#nan12513-bib-0039){ref-type="ref"}       Nissl                                  \>20 μm diameter, abundant Nissl substance                                   PD                               5                                                                                                                             58.5                                   76.60%                                                                                                                                                 69.80%                   --
  1995                                                   Arendt *et al*. [43](#nan12513-bib-0043){ref-type="ref"}       Nissl                                  \>20 μm diameter, visible nucleus, abundant Nissl substance                  PD                               6                                                                                                                             58.2                                   --                                                                                                                                                     --                       Approximately 75%[a](#nan12513-note-0004){ref-type="fn"} (*vs*. adult control); approximately 59.7% (*vs*. elderly control)
   2006                                                  Fujishiro *et al*. [35](#nan12513-bib-0035){ref-type="ref"}    ChAT                                   ChAT‐immunopositive cells                                                    DLB                              8                                                                                                                             75                                     --                                                                                                                                                     --                       Approximately 45%[a](#nan12513-note-0004){ref-type="fn"}
   2014                                                  Hall *et al*. [36](#nan12513-bib-0036){ref-type="ref"}         ChAT                                   ChAT‐immunopositive cells                                                    PD                               5                                                                                                                             60.4                                   --                                                                                                                                                     --                       n.s.
  PDD                                                    6                                                              60.2                                   --                                                                           --                               n.s.                                                                                                                                                                                                                                                                                                                                                 
  Other neurological diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  1983                                                   Whitehouse *et al*. [42](#nan12513-bib-0042){ref-type="ref"}   Nissl                                  \>30 μm diameter, abundant Nissl substance                                   Post‐encephalitic Parkinsonism   1                                                                                                                             50.3                                   85.16% increase                                                                                                                                        --                       --
  1983                                                   Arendt *et al*. [39](#nan12513-bib-0039){ref-type="ref"}       Nissl                                  \>20 μm diameter, abundant Nissl substance                                   Korsakoff\'s disease             3                                                                                                                             43.3                                   56.67%                                                                                                                                                 40.33%                   --
  1984                                                   Arendt *et al*. [47](#nan12513-bib-0047){ref-type="ref"}       Nissl                                  \>20 μm diameter, abundant Nissl substance                                   CJD                              1                                                                                                                             47                                     --                                                                                                                                                     --                       43% (right hemisphere); 39% (left hemisphere)
  1985                                                   Bauman *et al*. [48](#nan12513-bib-0048){ref-type="ref"}       Nissl                                  Visible nucleoli                                                             Infantile autism                 1                                                                                                                             29                                     11% (n.s.)                                                                                                                                             54% increase             --
  1995                                                   Arendt *et al*. [43](#nan12513-bib-0043){ref-type="ref"}       Nissl                                  \>20 μm diameter, visible nucleus, abundant Nissl substance                  Ageing                           11                                                                                                                            78.1                                   --                                                                                                                                                     --                       Approximately 38%[a](#nan12513-note-0004){ref-type="fn"} (*vs*. adult control)
  Korsakoff\'s disease with Wernicke\'s encephalopathy   6                                                              39.5                                   --                                                                           --                               Approximately 68%[a](#nan12513-note-0004){ref-type="fn"} (*vs*. adult control); approximately 48.4% (*vs*. elderly control)                                                                                                                                                                                                                          
  2013                                                   Rüb *et al*. [50](#nan12513-bib-0050){ref-type="ref"}          Nissl                                  All countable Nissl‐stained neurons                                          SCA2                             4                                                                                                                             54.8                                   74%                                                                                                                                                    72%                      --

Studies using immunohistochemical markers for the identification of cholinergic neurons within the nvlDBB are shaded in grey.

AChE, acetylcholinesterase; AD, Alzheimer\'s disease; ChAT, choline acetyltransferase; CJD, Creutzfeldt--Jakob disease; DLB, dementia with Lewy bodies; MSN, medial septal nucleus; NGFR, nerve growth factor receptor; n.s., no significance; nvlDBB, nucleus of the vertical limb of diagonal band of Broca; PD, Parkinson\'s disease; PDD, PD dementia; SCA2, spinocerebellar ataxia type 2.

Approximation from graphs within the study.

John Wiley & Sons, Ltd

The nvlDBB in PD and Lewy body dementias {#nan12513-sec-0014}
----------------------------------------

In contrast to AD, there have only been a small number of studies investigating neuronal loss in the nvlDBB in Lewy body disorders (Table [2](#nan12513-tbl-0002){ref-type="table"}). Whitehouse and colleagues used Nissl staining for neuronal counts and first reported 44.8% loss of nvlDBB neurons in two PD with dementia (PDD) cases but no significant change in three PD cases [42](#nan12513-bib-0042){ref-type="ref"}. Subsequently, using a neuronal counting criterion to include neurons larger than 20 μm in diameter, one study with five PD cases reported 76.6% loss of nvlDBB and 69.8% MSN neurons [4](#nan12513-bib-0004){ref-type="ref"} and another with six PD cases reported 59.7% loss of nvlDBB and MSN neurons [43](#nan12513-bib-0043){ref-type="ref"}. Recently, with ChAT‐immunohistochemistry, one study with eight dementia with Lewy bodies (DLB) cases reported significant Ch1/2 loss relative to age‐matched controls and AD cases [35](#nan12513-bib-0035){ref-type="ref"}. The cell loss was accompanied by a reduction of mean surface area of ChAT‐positive cell bodies, an indicator of cell size. Another study using post‐mortem tissues from a prospective and clinically well‐characterized cohort found an increased variation in cell number but no significant ChAT‐positive neuronal loss in the Ch1/2 region of five PD and six PDD cases, although a trend towards a decrease in neuron number was seen in progression from PD to PDD [36](#nan12513-bib-0036){ref-type="ref"}. Both studies have linked the change in nvlDBB neuronal count in Lewy body disease cases to an increase in ubiquitin‐positive, alpha‐synuclein Lewy neurite pathology in the CA2 subsector of the hippocampus, as reported by previous studies [44](#nan12513-bib-0044){ref-type="ref"}, [45](#nan12513-bib-0045){ref-type="ref"}, [46](#nan12513-bib-0046){ref-type="ref"}, which has been associated with cognitive impairment seen in Lewy body disorders.

The nvlDBB in other neurological conditions {#nan12513-sec-0015}
-------------------------------------------

Degeneration of the nvlDBB is not exclusive to neurodegenerative diseases (Table [2](#nan12513-tbl-0002){ref-type="table"}). Indeed, an approximately 38% nvlDBB and MSN neuronal loss has been reported in aged brains (mean age at death = 78.1) when compared to younger adult controls [43](#nan12513-bib-0043){ref-type="ref"}. In Korsakoff\'s disease, neuronal loss within the nvlDBB has been reported to be about 50% [39](#nan12513-bib-0039){ref-type="ref"}, [43](#nan12513-bib-0043){ref-type="ref"}. Single case studies on post‐encephalitic Parkinsonism [42](#nan12513-bib-0042){ref-type="ref"}, Creutzfeldt‐Jakob disease [47](#nan12513-bib-0047){ref-type="ref"} and infantile autism [48](#nan12513-bib-0048){ref-type="ref"} have all reported varying degrees of alteration in neuronal count/density within the nvlDBB. Interestingly, severe basal forebrain cholinergic degeneration has been reported in spinocerebellar ataxia (SCA) types 1 (SCA1) and 2 (SCA2) with relatively well‐preserved cognitive function [49](#nan12513-bib-0049){ref-type="ref"}, [50](#nan12513-bib-0050){ref-type="ref"}. In particular, one study reported neuronal loss in the MSN (72% loss), nvlDBB (74% loss) and nbM (86% loss) in four SCA2 cases compared with controls without significant correlation with tau pathology according to Braak and Braak AD stage [50](#nan12513-bib-0050){ref-type="ref"}, indicating a possible causal role of polyglutamine expansion in the death of basal forebrain cholinergic neurons.

Consideration of the noncholinergic components in the cholinergic basal forebrain complex {#nan12513-sec-0016}
=========================================================================================

As discussed previously, 90% of nbM magnocellular neurons in the primate basal forebrain express the cholinergic marker, ChAT [7](#nan12513-bib-0007){ref-type="ref"}. However, the proportion of cholinergic to noncholinergic neurons is much smaller in rostral cholinergic groups (10% in MSN, 70% in nvlDBB and 1% in nhlDBB). Therefore, previous studies using Nissl staining for quantification of neurons in the MSN and nvlDBB will also be describing pathology in the noncholinergic components of the basal forebrain. The neurochemical profiles of noncholinergic rostral basal forebrain neurons have been extensively investigated in rodents and nonhuman primates. Tyrosine‐hydroxylase‐positive neurons have been found in the basal forebrain [51](#nan12513-bib-0051){ref-type="ref"}, while γ‐aminobutyric acid (GABA)‐ergic [52](#nan12513-bib-0052){ref-type="ref"} and glutamatergic neurons [53](#nan12513-bib-0053){ref-type="ref"} form the largest noncholinergic hippocampal‐projecting group within MSN/nvlDBB. In rodent studies, low frequency theta rhythm in the hippocampus is generated in the MSN‐nvlDBB, mainly through GABAergic output neurons, and contributes to spatial learning and memory [54](#nan12513-bib-0054){ref-type="ref"}, [55](#nan12513-bib-0055){ref-type="ref"}. GABAergic output neurons from the MSN/nvlDBB form synaptic contacts with hippocampal interneurons and act as pacemaker cells for theta rhythm with disinhibition of hippocampal pyramidal neurons [55](#nan12513-bib-0055){ref-type="ref"}. Recent studies also showed glutamatergic neurons modulate theta rhythm via local modulation of GABAergic neurons within MSN/nvlDBB [56](#nan12513-bib-0056){ref-type="ref"}. Since MSN/nvlDBB neuronal loss was initially reported in AD cases with little or no significant loss in the ChAT‐immunopositive component, it could be hypothesized that there may be a greater GABAergic and glutamatergic MSN/nvlDBB neuronal loss in AD.

NGF and its receptors (high affinity, trkA and low affinity, p75^NTR^) colocalize within the human cholinergic basal forebrain [33](#nan12513-bib-0033){ref-type="ref"}, [57](#nan12513-bib-0057){ref-type="ref"}, [58](#nan12513-bib-0058){ref-type="ref"} and reduced NGFR levels and mRNA expression were reported in the nbM, but not the nvlDBB, of AD brains [33](#nan12513-bib-0033){ref-type="ref"}, [41](#nan12513-bib-0041){ref-type="ref"}. In addition, galanin, a 19 or 30‐amino acid long peptide in human brain, is coexpressed by basal forebrain cholinergic neurons. In AD and PD, galanin was shown to display a higher degree of presence ('hyperinnervation') in surviving ChAT‐positive neurons, particularly in the anterior basal forebrain [59](#nan12513-bib-0059){ref-type="ref"}, [60](#nan12513-bib-0060){ref-type="ref"}, [61](#nan12513-bib-0061){ref-type="ref"}.

Functional correlates to the differential pattern of nvlDBB cell loss in Alzheimer\'s and PD {#nan12513-sec-0017}
============================================================================================

Functional connections of the nvlDBB in the human brain remain largely unknown, but case studies from specific vascular lesions have provided some clues. There are two major sources of vascular supply to the basal forebrain. The anterior/septal sector of the basal forebrain (including MSN and nvlDBB) is supplied by perforator arteries of the anterior communicating artery; the caudal/horizontal sector (including the nhlDBB and nbM) is supplied by the anterior lenticulostriate branches from the proximal (A1) sector of the anterior cerebral artery [62](#nan12513-bib-0062){ref-type="ref"}.

Amnesia and Korsakoff\'s syndrome‐like symptoms have been reported in patients after repairs of ruptured anterior communicating artery aneurysm causing infarction of the anterior basal forebrain [63](#nan12513-bib-0063){ref-type="ref"}, [64](#nan12513-bib-0064){ref-type="ref"}, [65](#nan12513-bib-0065){ref-type="ref"}, [66](#nan12513-bib-0066){ref-type="ref"}, [67](#nan12513-bib-0067){ref-type="ref"}, [68](#nan12513-bib-0068){ref-type="ref"}, [69](#nan12513-bib-0069){ref-type="ref"}, [70](#nan12513-bib-0070){ref-type="ref"}, [71](#nan12513-bib-0071){ref-type="ref"}. These lesions tend to be widespread and affect multiple basal forebrain nuclei and fibre tracts. Nevertheless, two studies reported cases with relatively discrete basal forebrain lesions [72](#nan12513-bib-0072){ref-type="ref"}, [73](#nan12513-bib-0073){ref-type="ref"}. In one of the cases reported by Damasio and colleagues, surgical clipping of an aneurysm at the A1 and A2 junction of the left anterior cerebral artery was performed [72](#nan12513-bib-0072){ref-type="ref"}. The anatomical regions affected by this lesion were similar to a case reported by Abe and colleagues showing an isolated lesion at the right nvlDBB, anterior hypothalamus and lamina terminalis [73](#nan12513-bib-0073){ref-type="ref"}. Hypoperfusion caused by the lesion extended to both sides of the hemisphere as shown by single‐photon emission computed tomography scan using ^99m^Tc‐d, l‐hexamethyl propyleneamine oxime. In both cases, neuropsychiatric tests were performed and the patients exhibited anterograde and retrograde amnesia. However, there was a benefit with cueing that indicated a deficit in retrieval rather than encoding of memory. A similar amnestic profile was reported by Morris and colleagues on a case with surgical resection of a low‐grade astrocytoma at the right anterior basal ganglia region containing the nvlDBB [74](#nan12513-bib-0074){ref-type="ref"}. From these three cases, it is evident that the nvlDBB is involved in memory function and in particular memory retrieval.

According to the Movement Disorder Society Task Force consensus criteria on the diagnosis of PDD, patients with PDD may suffer impairment in free recall which improves with cueing [75](#nan12513-bib-0075){ref-type="ref"}. There is a general agreement that memory impairment in PD involves deficit in memory retrieval rather than storage/encoding memory as in AD [75](#nan12513-bib-0075){ref-type="ref"}. Therefore, it can be deduced that nvlDBB may be more significantly affected in Lewy body disorders than in AD. This is supported by an aforementioned post‐mortem study by Fujishiro and colleagues reporting a significant decrease in ChAT‐positive neurons in the nvlDBB of DLB cases relative to AD and age‐matched controls [35](#nan12513-bib-0035){ref-type="ref"}. However, a recent imaging study with 11 AD and 11 DLB patients failed to demonstrate difference in MSN/nvlDBB atrophy on structural MRI scans [76](#nan12513-bib-0076){ref-type="ref"}. Instead, only a trend reduction in MSN/nvlDBB volume was observed in AD (−17.5%) and DLB (−17.4%). This discrepancy may be due to the fact that *in vivo* MRI‐based measurement cannot distinguish whether neuronal loss or cell atrophy contributes to the volumetric changes. Thus, further post‐mortem studies will be required.

Ch2 and CA2: a possible connection? {#nan12513-sec-0018}
===================================

Similar to the nvlDBB, the hippocampal CA2 subfield is a relatively unexplored region in the human brain. Recently, using retrograde and adeno‐associated virus‐expressing anterograde tracers, reciprocal connections between the MSN‐nvlDBB and the CA2 have been identified in the mouse brain [77](#nan12513-bib-0077){ref-type="ref"}. Ubiquitin‐ and alpha‐synuclein‐immunopositive neuritic pathology in Lewy body disorders has been found confined to the CA2 subfield in the hippocampus [36](#nan12513-bib-0036){ref-type="ref"}, [44](#nan12513-bib-0044){ref-type="ref"}, [45](#nan12513-bib-0045){ref-type="ref"}, [46](#nan12513-bib-0046){ref-type="ref"}, in contrast to the preferential deposition of neurofibrillary tangles in the CA1 region in AD [78](#nan12513-bib-0078){ref-type="ref"}. Coincidentally, this is the subregion where the highest density of ChAT‐positive fibres and punctate immunoprecipitates can be identified in the human hippocampus [79](#nan12513-bib-0079){ref-type="ref"}. Although the presence of hippocampal dopaminergic innervation has been extensively reported in rodents [80](#nan12513-bib-0080){ref-type="ref"}, evidence of such projection in the human brain was lacking with one study failing to demonstrate the presence of monoaminergic fibre in the hippocampus of DLB and aged control brains using immunostaining with antityrosine hydroxylase antibodies [45](#nan12513-bib-0045){ref-type="ref"}. Significant hippocampal cholinergic depletion was found in PDD cases when compared with PD and control [36](#nan12513-bib-0036){ref-type="ref"}. The subfield‐specific protein aggregation pathology and cholinergic deficits in the hippocampus of Lewy body disorders appeared to be associated with the severe nvlDBB cholinergic depletion described in the sections above. As a result, it can be hypothesized that Lewy pathologies in the CA2 subregion of the hippocampus can cause neurodegeneration of the cholinergic component of the nvlDBB (Ch2) leading to deficits in retrieval memory, while a predominant noncholinergic neuronal loss of the nvlDBB may contribute to the encoding and storage memory deficits in AD (Figure [4](#nan12513-fig-0004){ref-type="fig"}).

![Proposed schema for the neurodegenerative changes within cholinergic and noncholinergic populations of the nvlDBB in Lewy body disorders and AD with possible clinicopathological correlates. AD, Alzheimer\'s disease; CA, Cornu Ammonis; Ch2, cholinergic population of the vertical limb of the diagonal band of Broca; DG, dentate gyrus; GABA, γ‐aminobutyric acid; LBD, Lewy body disorder; nvlDBB, nucleus of the vertical limb of the DBB.](NAN-44-647-g004){#nan12513-fig-0004}

Conclusion {#nan12513-sec-0019}
==========

The functional importance of the diagonal band in human cognition has long been recognized owing to its anatomical position in the limbic loop. However, the pathological significance of the nucleus of the diagonal band, particularly the nvlDBB, in neurodegenerative conditions has not been studied in detail. There has been a lack of consensus quantifying cholinergic cell loss in AD and Lewy body disorders primarily due to the following: (i) the absence of clear anatomical boundaries to delineate nvlDBB from surrounding magnocellular basal forebrain nuclei; (ii) application of size criteria for neuronal quantification discounting the possibility of cell shrinkage; and (iii) most studies attributing magnocellular neuronal loss in the nvlDBB to cholinergic nerve cells without use of a cholinergic immunohistochemical marker. Thus, by reviewing the history of DBB anatomy, we have established recommended sampling criteria for identifying the nvlDBB suitable for future clinicopathological studies. In addition, we recommend the use of specific cholinergic immunohistochemical markers such as ChAT for the identification and quantification of Ch2 (cholinergic component of nvlDBB) neurons. Further studies investigating the changes in the noncholinergic components of the nvlDBB, such as GABAergic neurons and glutamatergic interneurons, will also be needed.

Through the study of cases with discrete vascular or other lesions affecting the rostral basal forebrain, it can be deduced that the nvlDBB plays a discrete role in retrieval memory function, severely affected in Lewy body disorders. Extrapolating from existing clinicopathological studies, we propose an anatomical and functional connection between Ch2 and the CA2 subfield in the hippocampus which may be especially vulnerable to Lewy pathologies. Further clinicopathological investigations are now needed to test this hypothesis. With the development of novel tissue clearing techniques which have successfully been applied to post‐mortem human brain tissues for the visualization of anatomical structures and their connections in three dimensions [81](#nan12513-bib-0081){ref-type="ref"}, [82](#nan12513-bib-0082){ref-type="ref"}, [83](#nan12513-bib-0083){ref-type="ref"}, the detailed projection of cholinergic fibres from the nvlDBB in the human brain may be mapped out, shedding more light on the detailed role of the cholinergic nvlDBB in cognitive function.
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